Hypertrophic Cardiomyopathy Clinical Trial
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Summary
The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the course of 50 weeks of treatment.
Eligibility Criteria
Inclusion Criteria:
Diagnosed with Hypertrophic Cardiomyopathy with a left ventricular wall thickness greater than or equal to 13mm as determined by the echocardiogram obtained during the screening/baseline period
Left ventricular ejection fraction (LVEF) greater than or equal to 50% as determined by echocardiogram obtained during the screening/baseline period
Symptoms consistent with New York Heart Association (NYHA) Class II-III heart failure by physician assessment, or asymptomatic/NYHA Class I patients with:
NT-proBNP blood sample levels above 250 pg/ml and
peak VO2 of less than or equal to 80% of predicted based on age and gender as determined by cardiopulmonary exercise testing
Exclusion Criteria:
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for ≥7 days after stopping study drug
Patients with a resting or provokable left ventricular outflow tract gradient of greater than or equal to 30mm Hg
Septal reduction procedure within 3 months of the screening/baseline visit
History of atrial fibrillation within 6 months of the screening/baseline visit or placement of ICD for secondary prevention
Patients with a peak VO2 on the screening/baseline cardiopulmonary exercise test of > 80% of predicted based on age and gender
Patients who require treatment with ACE inhibitors, angiotensin receptor blockers (ARBs), or renin inhibitors
Known infiltrative or storage disorder such as Fabry disease, or amyloidosis
Known or suspected symptomatic coronary artery diseases or evidence of prior myocardial infarction
Systolic blood pressure of <100 mmHg or symptomatic hypotension during the screening/baseline period or treatment run-in period
Contraindication to ARB administration or prior history of angioedema
Persistent uncontrolled hypertension
Other protocol-defined inclusion/exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Stanford California, 94305, United States
Boston Massachusetts, 02114, United States
Ann Arbor Michigan, 48109, United States
Portland Oregon, 97239, United States
Berlin , 10789, Germany
Hamburg , 20246, Germany
Heidelberg , 69120, Germany
Kiel , 24105, Germany
Athens GR, 151 2, Greece
Heraklion Crete , 711 1, Greece
Seoul , 03722, Korea, Republic of
Seoul , 05505, Korea, Republic of
Valencia Comunidad Valenciana, 46010, Spain
El Palmar Murcia, 30120, Spain
Madrid , 28079, Spain
Madrid , 28222, Spain
London , EC1A , United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.